Showing results (101-110 of 451) with videos related to

Sort By:
Pageof 46
Gastroenterology|March 1, 2015
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel diseaseNiels Vande Casteele, Marc Ferrante, Gert Van Assche, et al.
Inflammatory Bowel Diseases|September 9, 2017
Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel DiseaseMaaike Vancamelbeke, Tim Vanuytsel, Ricard Farré, et al.
Journal of Crohn'S & Colitis|September 11, 2019
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Evelien Mertens, Erwin Dreesen, et al.
The American Journal of Gastroenterology|November 14, 2012
Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healingTalat Bessissow, Bart Lemmens, Marc Ferrante, et al.
Journal of Clinical Gastroenterology|December 3, 2019
Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease PatientsIris Detrez, Debby Thomas, Kristel Van Steen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Inflammatory Bowel Diseases|August 11, 2011
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.
Pageof 46